NCT05849129View on ClinicalTrials.gov

Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

October 1, 2030

Study Completion Date

October 1, 2031

Conditions
Lung Cancer
Interventions
DRUG

Ascorbic acid

High dose ascorbic acid delivered intravenously

OTHER

Normal Saline

0.9% NaCl solution

Trial Locations (1)

K1H8L6

RECRUITING

The Ottawa Hospital, Ottawa

Sponsors
All Listed Sponsors
collaborator

Ottawa Hospital Research Institiute

UNKNOWN

lead

The Canadian College of Naturopathic Medicine

OTHER